Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04223895
Other study ID # A83_04BE1917P
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date February 1, 2020
Est. completion date June 15, 2020

Study information

Verified date January 2020
Source Chong Kun Dang Pharmaceutical
Contact Yook-Hwan Noh
Phone 82-70-4665-9174
Email yook.noh@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacokinetics and Safety/Tolerability of CKD-386


Description:

Phase I clinical trial to compare the pharmacokinetics and tolerability of CKD-386 with co-administration of D012, D326, and D337 in healthy adult volunteers


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date June 15, 2020
Est. primary completion date March 4, 2020
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

1. Those who are over 19 years old at the screening visit

2. Those who weigh more than 50kg (45kg or more for women) at the screening visit and have a body mass index (BMI) within the range of 18-30kg/m^2

3. Those who meet the following conditions of blood pressure measured in a sitting position after sufficient rest at the screening visit

- Systolic blood pressure: 90mmHg or more and 139mmHg or less

- Diastolic blood pressure: 60mmHg or more and 89mmHg or less

4. Those who no congenital or chronic disease based on screening and no pathological symptoms or findings in medical examination results (e.g. EEG, ECG, chest and gastroscopy or gastrointestinal radiographs, if necessary)

5. The person in charge of the examination (or authorized test physician) who has determined that the test subject is suitable for the diagnostic test and electrocardiogram test such as hematology test, blood chemistry test, serology test and urine test performed according to the characteristics of the investigational drug product

6. Persons agreeing to exclude the possibility of pregnancy using appropriate contraceptive methods and not providing sperm or eggs from the date of first administration of the investigational drug to the 14th day after the last administration of the investigational drug

Exclusion Criteria:

1. Those who participated in other clinical trials (including bioequivalence studies) within 6 months before the first dose and received the investigational drug

2. Those who used drugs that induce and inhibit metabolic enzymes, such as barbital drugs, within one month before the first dose, or who used drugs that may interfere with this test within 10 days before the first dose

3. Those who have donated whole blood within 2 months before the first dose or component donation within 1 month, or have transfused within 1 month

4. Those who have had a history of gastrointestinal resection that may affect the absorption of the investigational drug (except appendectomy and hernia surgery)

5. A person who meets the following conditions within one month before the first administration date

- Excess alcohol: 21 cups / week for men and 14 cups / week for women.

[1 glass = 50 mL of shochu or 30 mL of liquor or 250 mL of beer]

- Smokers exceeding 20 cigarettes per day

6. Patients with the following diseases

- Patients with hypersensitivity to the main constituents or components of the investigational drug

- Severe hepatic impairment, biliary atresia or cholestasis

- Patients with hereditary angioedema or with a history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor antagonists

- Diabetes mellitus

- Patients with moderate to severe renal impairment [glomerular filtration rate (eGFR) <60 mL / min / 1.73m^2]

- Renal vascular hypertension patients

- Patients with active liver disease, including unexplained persistent serum transaminase elevations or elevated serum transaminase elevations greater than three times the normal upper limit

- Patients with myopathy or have a history of family or genetic history of myopathy

- Hypothyroidism

- If you have a history of muscle toxicity for other HMG-CoA converting enzymes or fibrate class drugs

7. Genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption

8. person who is considered to be unsuitable for participation in this clinical trial for reasons other than the above selection / exclusion criteria.

9. In the case of female volunteers, the suspected or lactating woman

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CKD-386 Formulation 1
A single oral dose of 1 tablet under fasting conditions for each period
CKD-386 Formulation 2
A single oral dose of 1 tablet under fasting conditions for each period
D012, D326 and D337
A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Outcome

Type Measure Description Time frame Safety issue
Primary AUCt of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337 AUCt: Area under the concentration-time curve 0(predose)~72 hours
Primary Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337 Cmax: Maximum plasma concentration of the drug 0(predose)~72 hours
Secondary AUCinf each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337 AUCinf: Area under the concentration-time curve from zero up to 8 0(predose)~72 hours
Secondary tmax each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337 tmax: Time to maximum plasma concentration 0(predose)~72 hours
Secondary AUCt/AUCinf each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337 AUCt/AUCinf: AUCt/AUCinf Ratio 0(predose)~72 hours
Secondary t1/2 each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337 t1/2: Terminal elimination half-life 0(predose)~72 hours
Secondary AUCt of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337 AUCt: Area under the concentration-time curve 0(predose)~72 hours
Secondary Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337 Cmax: Maximum plasma concentration of the drug 0(predose)~72 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A